重点产品
| 编号 | 化学名称 | Cas号 | 纯度 | 化学结构 |
|---|---|---|---|---|
| 1773101 | AAI-101 | 1001404-83-6 | 98.0% |  |
| AAI101(AAI101)是一种新型的增谱-乳酸酶抑制剂。AAI101(AAI101)与头孢吡 | ||||
| 77821 | ACY-775 | 1375466-18-4 | 98.0% by HPLC |  |
| ACY-775是一种组蛋白去乙酰化酶6(HDAC6)选择性抑制剂。 | ||||
| 2017878 | Elenbecestat ( E2609 ) | 1388651-30-6 | ≧98.0% | _1388651-30-6.png) |
| Elenbecestat是一种β-Site淀粉样前体蛋白裂解酶BACE）抑制剂，主要用 | ||||
| 2017889 | Roluperidone ( CYR-101 ) | 359625-79-9 | 98.0% |  |
| Roluperidone, also known as MIN-101, CYR-101, and MT-210, is a 5-HT2A and sigma 2 rec | ||||
| 90734 | RSM932A | 850807-63-5 | ≧98.0% | .png) |
| Choline kinase α (CHKA; here designated as ChoKα) is the first enzyme in the CDP-ch | ||||
| 121805 | L-778123 hydrochloride | 253863-00-2 | 98% |  |
| L-778123 hydrochloride is an inhibitor of FPTase and GGPTase-I with IC50 of 2 nM and | ||||
| 2073106 | Lerociclib HCl (G1T38 HCl) | 2097938-59-3 | ≧98.0% |  |
| Lerociclib HCl (G1T38 dihydrochloride)是一种分化型口服CDK4 / 6抑制剂，对 | ||||
| S510902 | Cenicriviroc ( TAK-652 ) | 497223-25-3 | 98% Min. |  |
| Cenicriviroc(TAK-652, TBR-652) 是一种CCR2和CCR5受体抑制剂，临床上它被用 | ||||
| 1711222 | Asciminib ( ABL001 ) | 1492952-76-7 | 99.35% |  |
| Asciminib, 也叫ABL001，是一种有效的BCR-ABL的变构抑制剂。ABL001在与尼 | ||||
| 18381 | JPH203 HCl ( Nanvuranlat ) | 1597402-27-1 | ≧95.0% | _1597402-27-1.png) |
| JPH203,也称为KYT- 0353,是一个强有力的和选择性(l型氨基酸转运蛋白 | ||||
| 18435 | Ritlecitinib ( PF-06651600 ) | 1792180-81-4 | ≧98.0% | _1792180-81-4.png) |
| Ritlecitinib ( PF-06651600 )是一种有效的选择性JAK3抑制剂，是一种具有 | ||||
| 184321 | Ensartinib ( X396 ) | 1370651-20-9 | >98% | _1370651-20-9.png) |
| Ensartinib is an orally available small molecule inhibitor of the receptor tyrosine k | ||||